Interleukin 6-guided Antibiotic Prescriptions in AECOPD Inpatients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-80
SponsorNingbo No. 1 Hospital
About this trial
In this multicenter, prospective, randomized controlled study, we aimed to figure out, compared with the global chronic obstructive pulmonary disease initiative (GOLD) guideline -guided antibiotic therapy, whether Interleukin 6 (IL6)-guided antibiotic therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) can lead to a reduction in the use of antibiotics without increasing the rate of treatment failure.
Eligibility criteria
Qualifiers
AECOPD patients admitted to hospitals
The exacerbation has lasted for at least 24 hours but equal to or less than 21 days
≥40 years of age but no more than 80 years old
With at least 10 pack-year history of smoking
Disqualifiers
Axillary temperature≥38°C
Acute pneumonia identified by X-Ray or CT of the chest
Severe respiratory failure requiring admittance to ICU
Comorbidities require antibiotic therapy (i.e. infection at another site, systematic infection, active chronic inflammatory condition, specific viral infection)
Trial design
Treatments tested in this trial
- Interleukin 6-guided antibiotic therapy
- GOLD-guided antibiotic therapy
Treatment groups
440 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov